



RESEARCH ARTICLE

miR-155 induction is a marker of murine norovirus infection but does not contribute to control of replication *in vivo* [version 1; peer review: 2 approved]

Lucy Thorne ^{1,2}, Jia Lu ¹, Yasmin Chaudhry ¹, Ian Goodfellow ¹

¹Division of Virology, Department of Pathology, University of Cambridge Addenbrooke's Hospital Cambridge, Cambridge, CB2 0QQ, UK

²Division of Infection and Immunity, University College London, London, WC1E 6BT, UK

v1 First published: 18 Apr 2018, 3:42 (<https://doi.org/10.12688/wellcomeopenres.14188.1>)

Latest published: 18 Apr 2018, 3:42 (<https://doi.org/10.12688/wellcomeopenres.14188.1>)

Abstract

Background: Due to their role in fine-tuning cellular protein expression, microRNAs both promote viral replication and contribute to antiviral responses, for a range of viruses. The interactions between norovirus and the microRNA machinery have not yet been studied. Here, we investigated the changes that occur in microRNA expression during murine norovirus (MNV) infection.

Methods: Using RT-qPCR-based arrays, we analysed changes in miRNA expression during infection with the acute strain MNV-1 in two permissive cell lines, a murine macrophage cell line, RAW264.7, and a murine microglial cell line, BV-2. By RT-qPCR, we further confirmed and analysed the changes in miR-155 expression in the infected cell lines, bone-marrow derived macrophage, and tissues harvested from mice infected with the persistent strain MNV-3. Using miR-155 knockout (KO) mice, we investigated whether loss of miR-155 affected viral replication and pathogenesis during persistent MNV-3 infection *in vivo* and monitored development of a serum IgG response by ELISA.

Results: We identified cell-specific panels of miRNAs whose expression were increased or decreased during infection. Only two miRNAs, miR-687 and miR-155, were induced in both cell lines. miR-155, implicated in innate immunity, was also upregulated in bone-marrow derived macrophage and infected tissues. MNV-3 established a persistent infection in miR-155 knockout (KO) mice, with comparable levels of secreted virus and tissue replication observed as for wildtype mice. However, serum anti-MNV IgG levels were significantly reduced in miR-155 KO mice compared to wildtype mice.

Conclusions: We have identified a panel of miRNAs whose expression changes with MNV infection. miR-155 induction is a marker of MNV infection *in vitro* and *in vivo*, however it does not contribute to the control of persistent infections *in vivo*. This finding suggests that the immune defects associated with miR-155 deletion, such as lower serum IgG levels, are also not important for control of persistent MNV-3 infection.

Keywords

norovirus, MNV, microRNA, miR-155, persistent infection

Open Peer Review

Reviewer Status

	Invited Reviewers	
	1	2
version 1 published 18 Apr 2018	 report	 report

1 **Charlie C. Hsu**, University of Washington, Seattle, USA

2 **Dirk Jochmans** , KU Leuven, Leuven, Belgium

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Lucy Thorne (l.thorne@ucl.ac.uk)

Author roles: **Thorne L:** Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Lu J:** Investigation; **Chaudhry Y:** Investigation; **Goodfellow I:** Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [106079], Sir Henry Wellcome Postdoctoral Fellowship to LT, and [097997 and 207498], Wellcome Trust Senior Fellowships to IG.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Thorne L *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Thorne L, Lu J, Chaudhry Y and Goodfellow I. **miR-155 induction is a marker of murine norovirus infection but does not contribute to control of replication *in vivo* [version 1; peer review: 2 approved]** Wellcome Open Research 2018, 3:42 (<https://doi.org/10.12688/wellcomeopenres.14188.1>)

First published: 18 Apr 2018, 3:42 (<https://doi.org/10.12688/wellcomeopenres.14188.1>)

Introduction

Noroviruses belong to the *Caliciviridae* family of small, positive strand RNA viruses. Human noroviruses (HuNoVs) are a major cause of viral gastroenteritis worldwide, causing around 2–3 million infections in the UK every year¹. The majority of infections are acute and occur in large outbreaks that sweep through places with close living environments, such as hospitals, at a considerable cost to the NHS². Although mortality rates are generally low, immunocompromised individuals are highly susceptible to HuNoV, often developing chronic infections, which represent a significant burden of morbidity in transplant recipients³.

Until very recently, HuNoVs had remained refractory to all attempts to establish a cell culture system. The recent demonstration of HuNoV replication in enteric organoids⁴ and a cultured B cell line⁵ represent significant breakthroughs. However, understanding of norovirus replication and in particular its interactions with the host cell currently still lags behind that of other viruses. As an alternative model system, murine norovirus (MNV) has been widely used to characterise norovirus replication. Like HuNoV, it is an enteric virus, which transmits by the faecal-oral route, and it has been found in wild and laboratory mice^{6,7}. It remains the only norovirus that replicates in cell culture to produce high titres of infectious virus and has a tropism for macrophage, dendritic cells, B and T cells, with a recent study also identifying a role of enterocytes *in vivo*^{5,8,9}. This, combined with the availability of reverse genetics systems^{10–12} and strains that cause both acute and persistent infections in the natural host^{6,11}, makes MNV a valuable model for characterising norovirus-host interactions.

MicroRNAs (miRNAs) are short non-coding RNAs, which post-transcriptionally silence over 50% of human mRNAs to fine-tune protein expression, contributing to the regulation of diverse cellular processes^{13,14}. Interactions with the cellular miRNA repertoire have been shown for a diverse range of viruses, including RNA, DNA, acute and persistent viruses. miRNAs have been reported to either promote or inhibit viral replication, in general by indirectly regulating expression of cellular cofactors or the immune response respectively^{15,16}, although direct interactions with viral RNAs have also been reported^{17,18}. As such a number of viruses actively manipulate cellular miRNA levels, either specifically or by targeting the miRNA processing machinery to initiate a global shutdown in miRNA biogenesis^{19–21}. Identifying the changes in miRNA expression that occur with infection can reveal new proteins or pathways that play a role in viral lifecycles.

To date there have been no reports on the interaction between noroviruses and the cellular miRNA machinery. Here, we aimed to determine whether MNV infection causes changes in miRNA expression in permissive cell lines, and whether any of the observed effects contribute to viral pathogenesis and affect the outcome of infection *in vivo*.

Methods

Cells

Murine macrophage cell lines RAW264.7 and microglial cell line BV-2 (provided by Jennifer Pocock, University College London) were maintained in Dulbecco's modified Eagles Medium (DMEM, Gibco) containing 10% fetal calf serum (FCS), penicillin (P) (100 SI units/mL) and streptomycin (S) (100 µg/mL) and 10 mM HEPES (pH7.6) at 37°C with 10% CO₂. For virus recovery BHK cells engineered to express T7 RNA polymerase (BSR-T7 cells, obtained from Karl-Klaus Conzelmann, Ludwig Maximilians University, Munich, Germany) were maintained in DMEM containing 10% FCS, penicillin (100 SI units/mL) and streptomycin (100 µg/mL) and 0.5 mg/mL G418. For preparation of bone marrow derived macrophage (BMDM), bone marrow cells were harvested from female C57BL/6 mice and were cultured in DMEM containing 10% fetal calf serum (FCS), penicillin (100 SI units/mL) and streptomycin (100µg/mL). For differentiation the supernatant from CMG14 cells, which contains macrophage colony stimulating factor (M-CSF), was added to the media for 5–7 days.

Virus recovery and infection

Recombinant viruses were rescued from cDNA clones containing either the MNV-1¹⁰ or MNV-3 genomes¹¹ using the reverse genetics system based on recombinant Fowlpox expressing T7 RNA polymerase, as previously described¹⁰. Fifty percent tissue culture infectious dose (TCID50) titrations were performed on RAW264.7 and BV-2 cells. For miRNA analysis, cell lines were infected with an acute strain of MNV (MNV-1) at an MOI of 0.1 TCID50/cell, or were mock infected. BMDM were infected with MNV-1 at an MOI of 10 TCID50/cell (as determined in RAW264.7 cells).

microRNA extraction and analysis

To analyse miRNA expression the small cellular RNA fraction (less than 200nt) was harvested at 20 hpi from cell lines, and 24 hpi from BMDMs, using the miRVana RNA isolation kit, as per manufacturer's instructions. For cDNA synthesis the Taqman miRNA reverse transcription kit was used (Life Technologies), according to manufacturer's instructions. 1000 ng of RNA extracted from infected and uninfected RAW264.7 cells and BV-2 cells were used with Megaplex RT primers, Rodent Pool A (Life Technologies). The pool contains primers specific to 335 and 238 mature unique mouse and rat miRNAs respectively, alongside primers for 4 specific endogenous controls. The cDNA was then used for qPCR using Taqman Rodent miRNA Array A cards (TDLA, Life Technologies, as per manufacturer's instructions), which contain primer-probe sets specific for 381 rodent miRNAs. The TDLA cards were run on the 7900HT T Fast Real-Time PCR System and the data was visualised and analysed for the Ct value of each miRNA by RQ manager software (Life Technologies). Further analysis was performed using Microsoft Excel. The Ct value for each miRNA was normalised against the Ct value for the endogenous control small nuclear RNA, U6, which did not change with infection. A two-fold change was used to indicate a significant change, as suggested

in the manufacturer's instructions. RT-qPCR was also performed using individual RT and PCR primer-probes specific to miR-155.

In vivo studies

For analysis of miR-155 expression, three-to-four week old female C57BL/6 mice were inoculated with 1000 TCID₅₀ of MNV-3 by oral gavage. Each group contained 3 mice and a control group was mock infected. The mesenteric lymph node (MLN), caecum and colon were isolated on day 2 post infection (dpi) for RNA extraction. miR-155 knock out mice (Jackson Laboratories) and wild type control C57BL/6 mice were inoculated with 10 TCID₅₀ of MNV-3 by oral gavage, with 5 mice in each group. Mice were weighed and faecal samples were collected on 1–7, 14 and 21 dpi. Serum samples were collected on days 0, 7, 14 and 21 pi, and mice were euthanized on day 21 pi. Tissue samples were harvested from separate groups on day 2 post infection.

RNA extraction and RT-qPCR for viral genome copies

Tissues were homogenised into RNA lysis buffer using ceramic beads (BioSpec Products) with a Fast Prep-24 homogeniser (MP Biomedicals). Faecal pellets were homogenised in PBS (100mg/mL), followed by centrifugation at 4000 rpm for 5 min, 4°C. RNA was extracted from 100 µL of supernatant using the GenElute total mammalian RNA kit (Sigma). Quantification of viral genome copies was performed by two-step RT-qPCR, with reverse transcription using with M-MLV RT (Promega) with random hexamers, as per manufacturer's instructions. qPCR was then performed on the cDNA using a Taqman Low Rox qPCR mastermix (Primer design), with primers (MNV-3 F: CCGCAGGAACGCTCAGCAG and R: GGCTGAATGGGGACG-GCCTG), and probe (ATGAGTGATGGCGCA). The Vii^a™ 7 Real time PCR machine was used with an initial denaturation step of 8 min at 95°C, followed by 50 cycles of 95°C for 10 s and 60°C for 1 min. The genome copy number was interpolated from the standard curve and was calculated per ng of RNA or per mg of stool depending on the sample, using Microsoft Excel. All graphs were produced using Graph Pad Prism V.5 Software.

ELISA for serum anti-MNV IgG

We performed ELISAs for detecting MNV-specific serum IgG in peripheral blood as previously reported (Hwang *et al.*, 2014, Wobus *et al.*, 2004). Briefly, MNV-3 virus-like particles (VLPs), kindly provided by Stephanie Karst (University of Florida, Gainesville, USA) were diluted 1:100 using carbonate buffer at pH 9.6 and 50 µl of VLPs were used per well to coat the Nunc MaxiSorp™ 96-well plate overnight at 4°C. Serum was collected as the supernatant after spinning the whole blood at 15,000 × g for 5 minutes at 4°C and was used at 1:100 dilution in 50 µl total volume. The reactions were developed by adding 100 µl 1-Step™ Turbo TMB-ELISA Substrate Solution (Life Technologies) and stopped by adding equal volume of 1N sulphuric acid solution. The absorbance at 450 nm were read and normalised absorbance were calculated by subtracting the mean absorbance of wells without primary antibody. The cutoff of positive results was determined as the mean + 3 × standard deviation of mock serum absorbance.

Results

To investigate changes in miRNA expression with norovirus infection, we infected two permissive cell lines, a murine macrophage cell line, RAW264.7, and a murine microglial cell line, BV-2, with an acute strain of MNV (MNV-1). We analysed miRNA expression at 20 hours post infection (hpi), a time selected to coincide with the peak in innate immune responses against MNV-1 previously identified²², as many macrophage miRNAs are thought to be involved in regulating interferon (IFN) responses²³. We found that only a small panel of miRNAs had altered expression as a result of MNV-1 infection in both RAW264.7 and BV-2 cells, whereas the majority did not change by more than 2-fold (Figure 1A). In total 6 miRNAs were upregulated by more than 2-fold in RAW264.7 cells: miR-687 (20.5x), miR-155 (10.5x), miR345-5p (5.5x), miR-658 (4.5x), miR-132 (3.1) and miR-210 (2.6x). In contrast, 5 miRNAs were downregulated in infected BV-2 cells: miR-let7b (4.0x), miR-207 (3.9x), miR-146a and miR-744 (both 2.1x), and miR-17 which was highly expressed in uninfected cells and decreased to below the level of detection with infection, representing the greatest change in BV-2s (Figure 1B). Taken together these results indicate cell-specific responses to viral infection. The only common response was the induction of miR-687 and miR-155, which were also upregulated in both cell lines but to a lesser extent in BV-2 cells than in RAW264.7 cells (6.1x and 2.0x respectively), (Figure 1B).

miR-155 is one of the most well-characterised miRNAs, with known links to innate immunity and an antiviral response^{24,25}. We therefore focused on miR-155, hypothesising that the increase in miR-155 may contribute to or potentially regulate the antiviral response to MNV infection. We first validated miR-155 induction in infected RAW264.7 and BV-2 cells using RT-qPCR. Compared to the data obtained using qPCR-based arrays, we detected an even greater increase in miR-155 expression in both infected cell types at the same time point post infection, with an induction of 100x in RAW264.7 cells (Figure 1A and Figure 2A). Also in line with the array data, miR-155 was more highly induced in infected RAW264.7 cells compared to infected BV-2s (Figure 2A), despite MNV-1 attaining similar levels of replication in both cell types (Figure 2B). We further validated the induction of miR-155 in MNV-1-infected bone-marrow derived macrophage cells (BMDMs). miR-155 expression was induced approximately 20-fold at 24 hpi in BMDMs, which rose to approximately 60-fold at 48 hpi (Figure 2C).

To determine whether miR-155 is upregulated during MNV infection *in vivo*, we infected immunocompetent mice with the persistent MNV-3 strain, and harvested tissues at day 2 post infection. This timing coincides with the peak in viral loads during the acute phase of infection, when virus can be detected in the caecum, colon and mesenteric lymph node (MLN)¹¹. We found that miR-155 was significantly increased in the caecum, the primary site for MNV replication¹¹, and a trend for induction was observed in the colon and MLN, although this was not significant.




Figure 2. miR-155 is upregulated in MNV-infected cells and tissues. (a) The fold change in miR-155 mature transcript levels with MNV-1 infection in RAW254.7 cells and BV-2s (0.1 TCID₅₀/cell) at 20 hpi. (b) MNV-1 replicates to similar levels in RAW264.7 cells as BV2 cells. Viral titres were determined by TCID₅₀. (c) miR-155 is upregulated over a time course of infection of MNV-1 in BMDMs. (d) miR-155 expression is induced in tissues infected with MNV-3 harvested at day 2 post infection from wildtype mice.

To determine whether miR-155 contributes to an antiviral response, we infected wildtype (WT) and miR-155 knockout (KO) mice with MNV-3. We choose to assess the role of miR-155 in a persistent model of infection as a recent study showed that miRNAs play a greater role in chronic infections than in acute infections, through regulating the expression of pro-inflammatory cytokines²⁶. MNV-3 typically causes a sub-clinical persistent infection in wildtype (WT) C57BL/6 mice¹¹. Similarly, we did not observe any weight loss in miR-155 KO mice, indicating that there was no increase in disease severity (data not shown). Accordingly, MNV-3 was secreted at similar levels in the KO and WT mice throughout 21 days of a persistent infection (Figure 3A). We harvested tissues at day 2 post infection to investigate if the lack of miR-155 affected dissemination of

the virus, but we observed no difference in viral genome copies in the colon, caecum or ileum (Figure 3B). Altogether this suggested that miR-155 does not play an essential role in controlling MNV replication in the acute or persistent phases of infection.

To determine whether miR-155 had any impact on the adaptive immune response to MNV-3, we compared development of the serum anti-MNV IgG response in infected miR-155 KO and WT mice. We found there was a lag in the production of serum IgG in the miR-155 KO mice, which had significantly lower levels compared to the WT mice at days 14, 21 and 28 hpi. Over this time course of the infection, the levels of serum IgG in the miR-155 KO mice did not reach those observed in WT mice.




Figure 3. MNV-3 persistence and replication is not affected in miR-155 KO mice. (a) MNV-3 is secreted at similar levels in the faeces from miR-155 KO mice as WT mice over the course of a persistent infection. (b) MNV-3 dissemination and replication in the tissues was comparable in miR-155 KO mice and WT mice at day 2 post infection. LOD indicated limit of detection. (c) miR-155 KO mice have impaired serum anti-MNV IgG levels compared to WT mice.

Discussion

In summary, we have identified a panel of miRNAs whose cell-type specific expression changes with MNV infection, indicating that MNV infection does not initiate a global shut-off in miRNA expression. miR-155 induction appears to be a marker of MNV infection in two permissive cell lines, as well as BMDMs and *in vivo* in infected tissues. However, the absence of miR-155 did not impact the course of infection or viral replication during persistent infection *in vivo*. This finding suggests that the immune defects associated with miR-155 deletion, such as lower serum IgG levels, are not important for control of persistent MNV infections.

miR-155 is one of the most highly studied miRNAs, upregulated in different cancers and with diverse cell-type specific roles reported^{27,28}. In macrophage, miR-155 has been associated with the innate antiviral response, as it is induced as a result of signaling through the RIGI/JNK/NF- κ B pathway²⁴. Upregulation of miR-155 promotes type I IFN signaling by silencing the negative regulator of the pathway, suppressor of cytokine signaling 1, (SOCS1)²⁴. Increased expression of miR-155 has also been shown to be accompanied by increased expression of pro-inflammatory mediators²⁹. As part of an inflammatory response the expression of miR-155 can also be increased indirectly through miR-342-5p²⁹, which was also induced in infected RAW264.7 cells and may have therefore contributed to the increase in miR-155 following MNV infection. As we observed no impact resulting from the loss of miR-155 on viral replication *in vivo*, in this study we did not further investigate which miR-155 targets are silenced in MNV-infected cells. A similar pro-inflammatory role has been demonstrated for miR146a in microglial cells³⁰, which we found was upregulated in BV-2 cells.

The defect we observed in the serum anti-MNV IgG response in miR-155 KO mice is consistent with their reported immune impairment, including defective TNF α production, reduced T-cell dependent antibody responses and a decrease in the proportion of INF γ -producing cells³¹. Interestingly, this suggests that the serum IgG response and these other aspects of the immune response do not play a role in controlling persistent MNV infections *in vivo*, as despite the impaired responses, MNV replication was unaffected. This finding is in contrast to a previous report where antibody responses were proposed to contribute to clearance of acute infections, and the control of MNV replication in persistently infected mice, although this was performed using mice defective in B cells and RAG1 KO mice³², suggesting this may be due to other defects in the antibody response than just serum IgG levels.

miR-687 was the most highly induced miRNA in both cell lines upon MNV infection, however very little is known about its function and expression profile. To date there has only been one

study on the function of miR-687, which links it to regulation of cell cycle progression and apoptosis in kidney cells, through regulation of the phosphatase PTEN³³. PTEN has recently been reported to have a further independent function in regulating innate immunity, by controlling activation and nuclear import of the master transcription factor governing IFN β production, IRF3³⁴. Both apoptosis and IRF3 activation are thought to occur during MNV infection^{35,36}, therefore whether miR-687 is involved in the regulation or crosstalk between these pathways will be an interesting avenue for future studies, which could reveal novel functions of miR-687 in the cellular response to viral stress.

In microglial BV-2 cells, downregulation of miR-17 was the greatest change associated with MNV infection. Further studies are required to validate this change in primary cells and infected tissues, but interestingly miR-17 has been shown to regulate autophagy through the suppression of Atg7 translation³⁷. Atg7 is known to be required for the INF γ antiviral response against MNV by promoting assembly of a complex of autophagy proteins, which in turn prevent formation of the MNV replication complex, although a direct mechanism linking INF γ and Atg7 has not been established³⁸. It is therefore interesting to speculate as to whether downregulation of miR-17 could provide this link, resulting in an increase in Atg7 translation, thereby contributing to the INF γ antiviral response.

Finally, the recently developed organoid⁴ and B cell culture systems⁵ for HuNoV now provide the opportunity to compare the cell-type specific responses in miRNA expression, with the aim of identifying novel cellular proteins involved in HuNoV replication.

Data availability

The raw data has been submitted to OSF <http://doi.org/10.17605/OSF.IO/S85DY>³⁹.

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by the Wellcome Trust [106079], Sir Henry Wellcome Postdoctoral Fellowship to LT, and [097997 and 207498], Wellcome Trust Senior Fellowships to IG.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Phillips G, Tam CC, Conti S, *et al.*: **Community Incidence of Norovirus-associated Infectious Intestinal Disease in England: Improved Estimates Using Viral Load for Norovirus Diagnosis.** *Am J Epidemiol.* 2010; **171**(9): 1014–1022. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Lopman BA, Reacher MH, Vipond IB, *et al.*: **Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002–2003.** *Emerg Infect Dis.* 2004b; **10**(10): 1827–1834. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Lee LY, Ladner DP, Ison MG: **Norovirus infection in solid organ transplant recipients: a single-center retrospective study.** *Transpl Infect Dis.* 2016; **18**(6): 932–938. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Ettayebi K, Crawford SE, Murakami K, *et al.*: **Replication of human noroviruses in stem cell–derived human enteroids.** *Science.* 2016; **353**(6306): 1387–1393. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Jones MK, Watanabe M, Zhu S, *et al.*: **Enteric bacteria promote human and mouse norovirus infection of B cells.** *Science.* 2014; **346**(6210): 755–759. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Wobus CE, Karst SM, Thackray LB, *et al.*: **Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages.** *PLoS Biol.* 2004; **2**(12): e432. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Smith DB, McFadden N, Blundell RJ, *et al.*: **Diversity of murine norovirus in wild-rodent populations: species-specific associations suggest an ancient divergence.** *J Gen Virol.* 2012; **93**(Pt 2): 259–266. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Grau KR, Roth AN, Zhu S, *et al.*: **The major targets of acute norovirus infection are immune cells in the gut-associated lymphoid tissue.** *Nat Microbiol.* 2017; **2**(12): 1586–1591. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Lee S, Wilen CB, Orvedahl A, *et al.*: **Norovirus Cell Tropism Is Determined by Combinatorial Action of a Viral Non-structural Protein and Host Cytokine.** *Cell Host Microbe.* 2017; **22**(4): 449–459.e444. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Chaudhry Y, Skinner MA, Goodfellow IG: **Recovery of genetically defined murine norovirus in tissue culture by using a fowlpox virus expressing T7 RNA polymerase.** *J Gen Virol.* 2007; **88**(Pt 8): 2091–2100. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Arias A, Bailey D, Chaudhry Y, *et al.*: **Development of a reverse-genetics system for murine norovirus 3: long-term persistence occurs in the caecum and colon.** *J Gen Virol.* 2012; **93**(Pt 7): 1432–1441. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Yunus MA, Chung LM, Chaudhry Y, *et al.*: **Development of an optimized RNA-based murine norovirus reverse genetics system.** *J Virol Methods.* 2010; **169**(1): 112–118. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Bartel DP: **MicroRNAs: target recognition and regulatory functions.** *Cell.* 2009; **136**(2): 215–233. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Ebert MS, Sharp PA: **Roles for microRNAs in conferring robustness to biological processes.** *Cell.* 2012; **149**(3): 515–524. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Chiang K, Liu H, Rice AP: **miR-132 enhances HIV-1 replication.** *Virology.* 2013; **438**(1): 1–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Bi Y, Liu G, Yang R: **MicroRNAs: novel regulators during the immune response.** *J Cell Physiol.* 2009; **218**(3): 467–472. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Jopling CL, Yi M, Lancaster AM, *et al.*: **Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.** *Science.* 2005; **309**(5740): 1577–1581. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Ahluwalia JK, Khan SZ, Soni K, *et al.*: **Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication.** *Retrovirology.* 2008; **5**: 117. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Cullen BR: **Viruses and microRNAs: RISCy interactions with serious consequences.** *Genes Dev.* 2011; **25**(18): 1881–1894. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Russo A, Potenza N: **Antiviral effects of human microRNAs and conservation of their target sites.** *FEBS Lett.* 2011; **585**(16): 2551–2555. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Backes S, Shapiro JS, Sabin LR, *et al.*: **Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism.** *Cell Host Microbe.* 2012; **12**(2): 200–210. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. McFadden N, Bailey D, Carrara G, *et al.*: **Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4.** *PLoS Pathog.* 2011; **7**(12): e1002413. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Witwer KW, Sisk JM, Gama L, *et al.*: **MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.** *J Immunol.* 2010; **184**(5): 2369–2376. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Wang P, Hou J, Lin L, *et al.*: **Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1.** *J Immunol.* 2010; **185**(10): 6226–6233. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Pareek S, Roy S, Kumari B, *et al.*: **MiR-155 induction in microglial cells suppresses Japanese encephalitis virus replication and negatively modulates innate immune responses.** *J Neuroinflammation.* 2014; **11**: 97. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Backes S, Langlois RA, Schmid S, *et al.*: **The Mammalian response to virus infection is independent of small RNA silencing.** *Cell Rep.* 2014; **8**(1): 114–125. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Ranganath P: **MicroRNA-155 and Its Role in Malignant Hematopoiesis.** *Biomark Insights.* 2015; **10**: 95–102. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Wan J, Xia L, Xu W, *et al.*: **Expression and Function of miR-155 in Diseases of the Gastrointestinal Tract.** *Int J Mol Sci.* 2016; **17**(5): pii: E709. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Wei Y, Nazari-Jahantigh M, Chan L, *et al.*: **The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis.** *Circulation.* 2013; **127**(15): 1609–1619. [PubMed Abstract](#) | [Publisher Full Text](#)
30. Rom S, Rom I, Passiatore G, *et al.*: **CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells.** *FASEB J.* 2010; **24**(7): 2292–2300. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Thai TH, Calado DP, Casola S, *et al.*: **Regulation of the germinal center response by microRNA-155.** *Science.* 2007; **316**(5824): 604–608. [PubMed Abstract](#) | [Publisher Full Text](#)
32. Chachu KA, Strong DW, LoBue AD, *et al.*: **Antibody is critical for the clearance of murine norovirus infection.** *J Virol.* 2008; **82**(13): 6610–6617. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Bhatt K, Wei Q, Pabla N, *et al.*: **MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury.** *J Am Soc Nephrol.* 2015; **26**(7): 1588–1596. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Li S, Zhu M, Pan R, *et al.*: **The tumor suppressor PTEN has a critical role in antiviral innate immunity.** *Nat Immunol.* 2016; **17**(3): 241–249. [PubMed Abstract](#) | [Publisher Full Text](#)
35. Bok K, Prikhodko VG, Green KY, *et al.*: **Apoptosis in murine norovirus-infected RAW264.7 cells is associated with downregulation of survivin.** *J Virol.* 2009; **83**(8): 3647–3656. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Thackray LB, Duan E, Lazear HM, *et al.*: **Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication.** *J Virol.* 2012; **86**(24): 13515–13523. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Comincini S, Allavena G, Palumbo S, *et al.*: **microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to Temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.** *Cancer Biol Ther.* 2013; **14**(7): 574–86. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Hwang S, Maloney NS, Bruinsma MW, *et al.*: **Nondegradative role of Atg5-Atg12/Atg16L1 autophagy protein complex in antiviral activity of interferon gamma.** *Cell Host Microbe.* 2012; **11**(4): 397–409. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Lucy T: **miR-155 Induction Is a Marker of Murine Norovirus Infection but Does Not Contribute to Control of Replication in Vivo.** *Open Science Framework.* 2018. [Data Source](#)

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 29 May 2018

<https://doi.org/10.21956/wellcomeopenres.15433.r33174>

© 2018 Jochmans D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Dirk Jochmans 

Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium

This manuscript by Thorne et al describes the first investigation on the role of miRNAs in norovirus infections. They discovered several miRNA's of which the expression levels significantly change upon infection with MNV-1 in cell lines, which is a unique contribution to the field. They also show that a knockout of miR-155 does not influence the replication of MNV-3 in a mouse model. Both these results are sufficiently innovative to warrant the publication of this paper. In general the paper is well written and integrates very well the current knowledge on the topic.

However there are two parts where we believe this paper could improve.

1. The cell line work has been done using MNV-1 while the animal work was performed with MNV-3. It is not impossible that the effect of norovirus on miR-155 is only apparent with MNV-1 and not with MNV-3. This would put the animal work in another perspective. It would therefore be very informative if the experiments described in fig 2.a, 2.b and 2.c are also performed with MNV-3. This may clearly demonstrate that also MNV-3 influences miR-155 expression *in vitro*. Now the only effect of MNV-3 on miR-155 expression is shown in fig 2.d but in our opinion, this is not sufficiently convincing to say that the effect is significant. In the first panel of fig 2.d the significance is indicated by "***" but it is not stipulated what the p value is here.
2. A second topic of discussion is the way the data is presented in figure 1. In our opinion, it is important to depict the fold change of expression level on a log scale. The expression levels are determined from Ct values that follow a normal distribution and for which a stdev can be calculated. If one log-transforms the Ct values to expression levels the normal distribution is lost and other statistics than stdev should be used. Therefore I would suggest that the authors calculate for each measurement the log(fold change over mock) and for these values calculate the average and stdev and show these on the y-axis of fig 1. This would also give a more clear presentation of the data around the 2-fold increase/decrease expression level. It would also benefit the reader significantly to plot the miR in a specific order and to put the expression of one miR in both cell lines next to each other. At this moment the reader cannot easily compare the expression levels of a particular miR between the cell lines.

In addition, we have some minor comments:

- In figure 1 the number of measurements are not indicated
- In the methods the manufacturer of the miRVana kit is not indicated
- In the first paragraph of the results section, the average values of the expression levels are indicated but not the statistics. An average of the log(fold change) and stdev could be indicated instead (see topic 2 above). The conclusion that miR-155 is upregulated in BV-2 cells is now difficult to conclude from fig 1.
- In the third paragraph of the result section the authors should refer to fig 2D
- In fig 3 LOD stands for limit of detection. Perhaps the authors mean limit of quantification?
- When referring to reference 32 in the conclusion the authors may want to comment that this was a paper studying MNV-1 and not MNV-3. It can be that IgG play a role in MNV-1 infections but not MNV-3 infections and vice versa for miR-155.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 21 May 2018

<https://doi.org/10.21956/wellcomeopenres.15433.r33130>

© 2018 Hsu C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Charlie C. Hsu**

Department of Comparative Medicine, University of Washington, Seattle, WA, USA

The manuscript “miR-155 induction is a marker of murine norovirus infection but does not contribute to control of replication *in vivo*” by Thorne et al. is a well written report describing the impact of MNV infection on microRNAs both *in vitro* and *in vivo*. The reported findings are novel in that this is the first report evaluating the interaction of noroviruses and miRNAs. The authors show that MNV indeed can modulate miRNA expression in cell lines, BMDM, and *in vivo*. They report that miR-155, a microRNA involved with type I interferon signaling, is upregulated both *in vitro* and *in vivo*, but that miR-155 knockout mice did not show any differences in viral replication compared to infected wild-type mice despite having lower serum anti-MNV antibody levels. These results suggest that miR-155 does not significantly contribute to control of MNV replication. This manuscript is well organized and the authors do a nice job explaining their rationale for the experiments and they also thoughtfully discuss and interpret their results.

This reviewer had only minor comments, suggestions, and thoughts:

- It is suggested to include the full nomenclature on the C57BL/6 wild-type mice, as well as the miR-155 knockout mice from Jackson Laboratories in the Methods to provide the readers information on which C57BL/6 substrain was used, and for accuracy of the miR-155 mouse strain.
- It would be interesting to see whether lack of miR-155 and the lower anti-MNV antibody levels in miR-155 knockout mice would impact viral levels and persistence in MNV-1, a typically non-persistent viral strain. Although the authors provide an adequate explanation of why they used MNV-3, a persistent viral strain, for the *in vivo* study, rather than the MNV-1 that was used *in vitro*, this reviewer is curious if the lower antibody levels may perhaps prevent clearance of MNV-1 in these mice, or if virus persists longer than in WT mice but ultimately gets cleared. These results may shed light on the importance (or lack of importance) of miR-155 associated immune defects on non-persistent viral strain.
- It is suggested to include information on the statistical tests used to evaluate differences if not already included in the manuscript.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
